Rebecca B. Klisovic MD

Oncology•Cleveland, OH

Hematologic Oncology

Assistant CMIO UH Seidman Cancer Professor - Hematology & Oncology

Join to View Full Profile

UH Cleveland Medical Center11100 Euclid Ave Department of Medicine-Hematology and OncologyCleveland, OH 44106
Phone+1 216-844-3951
Fax+1 216-844-5234

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004
University of North Carolina HospitalsResidency, Internal Medicine, 1997 - 2000
Ohio State University College of MedicineClass of 1997
Case Western Reserve UniversityBS, Biomedical Engineering, 1989 - 1993

Certifications & Licensure

OH State Medical License 2001 - 2025
GA State Medical License 2017 - 2022
NC State Medical License 1998 - 2001
American Board of Internal Medicine Medical Oncology
EpicPhysician Builder

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2007 Aug 01
Completed
Phase 2
Correlative Biomarker Study in Patients With Myeloproliferative Disorders Start of enrollment: 2007 Apr 01
Completed
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2010 Aug 01
Completed
Phase 1
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2011 Jan 20
Completed
Phase 1
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 3
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) Start of enrollment: 2013 Apr 01
Terminated
Phase 2
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis Start of enrollment: 2013 Nov 01
Terminated
Phase 2
AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Sep 17
Completed
Phase 1
L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
ACTIVE_NOT_RECRUITING
PHASE3
CAR-T Long Term Follow Up (LTFU) Study Start of enrollment: 2015 Nov 02
RECRUITING
PHASE3
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2016 Mar 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.
Chenyu Lin, Anand A Patel, Dezheng Huo, Theodore Karrison, Koen van Besien
Blood Advances. 2024-11-26
6 citations
Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
Bhavana Bhatnagar, Qiuhong Zhao, Alice S Mims, Sumithira Vasu, Gregory K Behbehani
Leukemia & Lymphoma. 2023-12-01
41 citations
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphobla...
Anjali S Advani, Anna Moseley, Kristen M O'Dwyer, Brent L Wood, Min Fang
Journal of Clinical Oncology. 2022-05-10

Lectures

Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with N...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationJune 2017

Press Mentions

OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesOctober 31st, 2019
Turning Points: Together in Sickness, Married in HealthAugust 1st, 2016
Bone-Marrow Donor Travels from Israel for Wedding of Transplant RecipientApril 29th, 2016
Join now to see all

Grant Support

Gti-2040: An Anti-Sense Strategy To Reduce Ribonucleotide Reductase In AMLNational Cancer Institute2009–2010

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
ASBMT
Member
American Medical Informatics Association - AMIA
Member